ProPhase Labs’ Resolution for 2025: Nail Down a ‘Liquidity Event’
The company has lost nearly $36 million since 2023, but its CEO is aggressively pursuing new revenue options
Laboratory Industry Report
Keeps You Up-to-Date on Lab Business and Competitive Strategy, Market Trends and Opportunities, and M&A and Investment Activity in Today’s Diagnostic Lab Industry
Subscribe today for access to
Articles and Reports
Out with the Old: The 2024 Clinical Lab Experience
What challenges and opportunities affected the experience of medical lab professionals in 2024—and what might the new year bring?
FDA Watch: How Could the Change in US Government Affect IVDs and Labs?
Experts say new leadership could impact the cost and availability of IVDs as well as patients’ ability to afford lab testing
Diagnostic Deals: The Fate of Illumina-PacBio Merger Hangs in the Balance
Will they or won’t they? The suspense continues over whether Illumina’s proposed rescue of Pacific Biosciences will actually close. The $1.2 billion cash merger, which was originally expected to close in mid-2019, is now on indefinite hold due to regulatory antitrust
Pay rates, vacations while recovering, gig economy
Department of Labor enters final stage of update to ‘regular rate’ rule under FLSA. As we have discussed previously in these updates, the Department of Labor has been working to update the definition
Kellison and G2 Intelligence Honor Dr. Sidney Goldblatt
...
Already a member? Log in here
Diagnostic Deals: A roundup of the key mergers, acquisitions, alliances, licenses and other strategic transactions from the past month
Although briskness in alliances partially offset sluggishness in M&A, October was far less dynamic than September for strategic deal making within the diagnostics sector. Here’s an overview of the key deals that did come down over the 4-week period beginning in late September 2019.
FDA Watch: New Process for Simultaneous Review IVD Tests Used in Cancer Drug Trials
Typically, in vitro diagnostic (IVDs) tests used in investigational cancer drug trials require two submissions: one for the IVD test and another for the drug. But on Oct. 9, the FDA issued final guidance allowing companies to submit for simultaneous review for the clinical trial.
The DX Pipeline: A roundup of the month’s key new product launches
With 10 days still left to run, October was shaping up to be the busiest month of 2019 for new product launches. Here’s a summary of the key diagnostic products unveiled so far:
Industry Buzz: Qiagen and the Terrible, Horrible, No Good, Very Bad Day
...
Already a member? Log in here
Special Report: Long Awaited Kickback Relief Rules Keep Labs in the Cold
...
Already a member? Log in here
The DX Pipeline: A Roundup of the Month’s Key New Product Launches
Here's a summary of the key product launches announced from late August through the third week of September, 2019:
FDA Watch: New NGS Data Guidance May Ease Antiviral Drugs & Companion Test Approvals
A new FDA Technical Specifications document (Tech Doc) lists recommendations for sponsors on use of next generation sequencing data to secure approval of new antiviral drugs and related diagnostic tests providing crucial guidance on six key issues.
